Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that longer exposure to 5α-reductase inhibitors significantly increased the risk of persistent erectile dysfunction, especially in younger men exposed to finasteride.

This study reports that clinical trials of finasteride for androgenic alopecia provide insufficient and systematically biased safety data, with most participants unrepresentative of those in pivotal trials that led to FDA approval.

Finasteride helps improve hair growth in men with hair loss but may increase the risk of erectile dysfunction.

This review examines the sexual side effects of 5α-reductase inhibitors like finasteride, highlighting the increased risk of erectile dysfunction, libido reduction, and potential contribution to depression without new clinical findings.

This review discusses post-finasteride syndrome, highlighting occasional adverse sexual and systemic effects in men and women, but reports no new research findings while emphasizing the need for better education about the drug's risks.

This article evaluated evidence on finasteride's effects on male reproductive health, finding contradictory data about its adverse effects, but consensus that such cases are infrequent in research and clinical settings.

This study found that daily oral finasteride may increase hair count and improve hair appearance assessments in men with androgenetic alopecia, but it also appears to raise the risk of sexual dysfunction.

This study found that oral finasteride 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss over two years.

This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.

This review suggests that while finasteride for male pattern hair loss was previously considered safe, there is now evidence associating 5-α reductase inhibitors with significant sexual and reproductive side effects.

This review discusses sexual side effects in men with androgenic alopecia treated with 5-alpha reductase inhibitors and reports no new clinical findings.

Finasteride for female hair loss has low side effects, more research needed.

This review discusses the use of finasteride for treating androgenetic alopecia in men, noting its effectiveness in maintaining and regrowing hair on the scalp and top of the head.

Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.

This article discusses Propecia in dermatology but provides no new research findings.

The authors concluded that finasteride and dutasteride might have serious side effects, including persistent sexual dysfunction for some, necessitating further research and vigilant risk-benefit analysis.

This study evaluated dermatologists' beliefs and counseling practices regarding finasteride's adverse effects, revealing that while 51% believed it could cause sexual side effects, fewer associated it with depression or infertility, highlighting a need for increased awareness and improved patient counseling.

Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.

This article reviews the use of finasteride for treating male pattern hair loss, highlighting its mechanism of action in reducing DHT and noting its safety profile with some common adverse effects.

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.

This article reviews the mechanism, use, and alternatives for finasteride in dermatology and provides no new clinical results.

This paper proposes that gut dysbiosis plays a crucial role in Post-Finasteride Syndrome by possibly contributing to both androgenic and non-androgenic symptoms, and may explain fluctuating symptom cycles better than static genetic explanations.

This paper hypothesizes that gut dysbiosis acts as a key factor in Post-Finasteride Syndrome, potentially explaining its symptom patterns beyond androgen receptor silencing.

This study found that acceptance of hair loss is associated with lower psychological distress in young men, highlighting its adaptive role compared to compensation and avoidance strategies.

Finasteride can cause low platelet count in rare cases.

This study found that men experiencing long-term symptoms after finasteride use for androgenetic alopecia frequently reported loss of penis sensitivity and anhedonia, among other effects, indicating potential post-finasteride syndrome.

This review discusses post-SSRI sexual dysfunction and post-finasteride syndrome, highlighting unknowns about their true incidence and underlying causes, and reports no new clinical results.

This review discusses post-finasteride syndrome, emphasizing its serious psychological and cognitive symptoms and the need for more research and awareness in the medical community, but provides no new clinical findings.